CRISPR/Cas9-mediated DGK knockout human CAR T-cell therapy (ToolGen/Brigham & Women's Hospital)

N/A

Report date: 2025/03/19 09:00:36

Base Information

Drug NameCRISPR/Cas9-mediated DGK knockout human CAR T-cell therapy (ToolGen/Brigham & Women's Hospital)
Drug Alias NameCRISPR gene-edited CAR-T cell
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesToolGen Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalToolGen Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A